Acute coronary syndrome, atrial fibrillation, dyslipidaemias and advanced heart failure are medical problems increasingly absorbing a significant amount of resources all over the world and their treatment is rapidly evolving.
Aside to the intensified resort to mechanic revascularisations procedures (i.e. percutaneous coronary intervention), to electrophisiological ablation procedures, many new antiplatelet and anticoagulant drugs have been developed in the last years. The new agents offer great opportunities in patients' treatment, but their use is still conflicting in the different settings. Furthermore, doctors encounter daily clinical situations, where the use of these drugs are not clearly codified and remains uncertain.
Recently an increased attention to adequate cholesterol and lipid managment has been promoted. Guidelines have been updated and a stronger role for PCSK9 (Proprotein convertase subtilisin/kexin type 9) has been advocated. Drugs that block PCSK9 can lower low-density lipoprotein cholesterol (LDL-C), and Phase III clinical trials have assessed their safety and efficacy in humans and determined that they can improve outcomes in heart disease.
Similar increased attention to heart failure treatment has been stressed after latest update of Heart Failure Guidelines and there is a progressive diffusion in the use of new drugs such as sacubitril/valsartan.
Antiplatelet, anticoagulant, lipid lowering and heart failure therapies play a central role in modern cardiology and proper knowledge of their indication should be part of every physician's expertise.
Inizio evento | Venerdì 29 Settembre 2017 11:00 |
Termine evento | Sabato 30 Settembre 2017 15:40 |
Costo per persona | 470,00 € |
Ore totali | 12 |
Orario dettagliato |
29/09: dalle 11.00 alle 17.20 30 alle 09 09.00/12.40 30/09: dalle 13.40 alle 15.40 |
Docenti |
Responsabile Scientifico: Cemin Roberto |
Luogo | BOLZANO (BZ) - FOUR POINTS BY SHERATON BOLZANO |
Allegato | TYR0117BZ2909.pdf |